Marín-Huerta E, Moro Serrano C, Novo L, Madrid A H, Lage J, Mestre J L, Vargas C, Yepes L, Aguilera A
Unidad de Arritmias, Hospital Ramón y Cajal, Madrid.
Rev Esp Cardiol. 1994 Oct;47(10):706-9.
We have performed 2 implantations of transvenous automatic cardioverter defibrillator in a cardiac laboratory devoted to electrophysiology and pacemaker implantation. This is a preliminary experience with a novel implant strategy. Cardiologists were the primary operators. The automatic cardioverter defibrillator were placed in a subcutaneous pectoral region, with a non-thoracotomy lead system. The automatic cardioverter defibrillator were two Medtronic 7219D PCD Jewel, with a Transvene system. There were no perioperative complications. Acceptable defibrillation threshold were obtained in both patients, 12 and 20 J, respectively. Leads were inserted percutaneously through the left subclavian vein. After 8 months of follow-up the patients continue to tolerate the device satisfactorily. Implantation of automatic cardioverter defibrillator systems by trained cardiologists in an electrophysiology laboratory is safe and feasible. Moreover, its cost-effectiveness is superior, the saving includes the surgeons, and the reduction of stay in unit of intensive care and hospitalization.
我们在一个专门进行电生理和起搏器植入的心脏实验室中进行了2例经静脉自动心脏复律除颤器植入手术。这是一种新型植入策略的初步经验。心脏病专家是主要手术操作者。自动心脏复律除颤器放置在皮下胸肌区域，采用非开胸导联系统。自动心脏复律除颤器为两台美敦力7219D PCD Jewel，带有经静脉系统。围手术期无并发症。两名患者分别获得了可接受的除颤阈值，分别为12焦耳和20焦耳。导联经皮通过左锁骨下静脉插入。经过8个月的随访，患者对该设备仍能满意耐受。由训练有素的心脏病专家在电生理实验室植入自动心脏复律除颤器系统是安全可行的。此外，其成本效益更高，节省包括外科医生费用，以及减少重症监护病房停留时间和住院时间。
